Question 1

What are the main strengths of investing in MCK?

Accepted Answer

The main strengths of investing in McKesson Corporation include: Sustainalytics "Strong" ESG management rating with comprehensive impact reporting, Critical healthcare infrastructure delivering 1/3 of North American medications, 18% revenue growth with expanding margins in specialty pharmaceuticals.

Question 2

What are the potential drawbacks of investing in MCK?

Accepted Answer

Potential drawbacks of investing in McKesson Corporation include: Pharmaceutical distribution role in opioid crisis creates reputational risks, Drug pricing transparency pressures impact social responsibility scores, Regulatory scrutiny and potential liability from controlled substances distribution.

Question 3

What are the key financial metrics for MCK?

Accepted Answer

Key financial metrics for McKesson Corporation include: Market Cap: $2.33 billion, Current Price: $133.06, Dividend Yield: 4.33%.

McKesson Corporation

Detailed View

MCK

ESG Ratings